Six dividend stocks in a $500,000 portfolio sound like a solid income plan, but where you hold them decides how much of that income you actually keep, and the difference compounds into…
Retirees chasing income face a choice that looks simple on paper but hides a tax trap, a reinvestment problem, and a dividend cut risk that most income comparisons never mention.
A portfolio built entirely around stocks and equity funds can generate $12,300 a month, or $147,600 a year, in income. The no-bond design stands out with the 10-year Treasury yielding 5.2%. Using…
Pfizer's dividend yield has climbed well above what most blue-chip drugmakers offer, and the reason behind that gap matters far more than the number itself.
Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock trades at $207.80, up 5%, after its addition to the NASDAQ 100 took effect. That entry places a company once valued as a COVID-19 vaccine…
Cantor Fitzgerald just bumped price targets on Eli Lilly, AbbVie, Merck, and Pfizer, but higher targets do not mean equal conviction. The firm's split between Overweight and Neutral ratings reveals a sharp…
Four household names are dangling yields above 5% at a moment when their earnings, cash flow, and debt levels raise serious questions about whether those payouts can last. Retirees counting on that…
When the paycheck stops at retirement, your portfolio has to carry the weight, and one dividend cut can force painful choices between a tighter budget and selling shares at the worst moment.…
Pfizer's yield towers over Johnson and Johnson's, but a bigger number on paper can hide serious risks underneath. Before you chase that payout, consider what a frozen dividend, rising debt, and a…
Johnson & Johnson just logged its 64th straight year of dividend growth, but biosimilar threats, a MedTech slowdown, and lingering talc litigation raise a real question about whether that streak justifies buying…
Some of the most recognizable dividend stocks in the market have been paying shareholders with money they do not actually earn, and the accounting trail reveals exactly how far six of them…
Moderna stock has turned a handful of patient shareholders into believers, but a gain this size forces a choice that most investors never plan for in advance. The pipeline promise is real,…
A plague headline out of Siberia lifted vaccine stocks, and the agencies closest to the case have since described the risk as low. That reversal in sentiment lands hardest on Novavax (NASDAQ:NVAX),…
Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are trading as though the company’s messenger RNA (mRNA) cancer vaccine has already cleared its final test, even though the complete Phase 3 dataset…
Ten consecutive earnings beats and a shrinking COVID hangover have Wall Street split on whether Pfizer deserves a breakout or a ceiling, and the answer hinges on a single pipeline deal that…
